Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.36 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | ITGAL | P20701 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 2/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL431787 | 1.00 | ITGB2 (0.44) | ITGB2ICAM1ITGALLMNACRHBP | |
| Hydrochloric Acid SCHEMBL29484132 | 1.00 | ITGB2 (0.44) | ITGB2ICAM1ITGALLMNACRHBP | |
| Hydrochloric Acid SCHEMBL431786 | 1.00 | ITGB2 (0.44) | ITGB2ICAM1ITGALLMNACRHBP | |
| Hydrochloric Acid SCHEMBL598998 | 1.00 | ITGB2 (0.44) | ITGB2ICAM1ITGALLMNACRHBP | |
| Hydrochloric Acid SCHEMBL29484136 | 1.00 | ITGB2 (0.44) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL193981 | 0.98 | ITGB2 (0.46) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL29858755 | 0.98 | ITGB2 (0.46) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL2627039 | 0.98 | ITGB2 (0.46) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL30563663 | 0.98 | ITGB2 (0.46) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL29764040 | 0.98 | ITGB2 (0.46) | ITGB2ICAM1ITGALLMNACRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559481-B2 | Quinoline derivatives | ELANCO ANIMAL HEALTH GMBH (DE) | 2026-02-24 | — | — | US | disclosed |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12435068-B2 | Anthelmintic compounds | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-10-07 | — | — | US | disclosed |
| US-12391682-B2 | Isoquinoline derivatives and their use for the treatment of parasitic infections | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-08-19 | — | — | US | disclosed |
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-04-24 | — | — | US | disclosed |
| EP-4003524-B1 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PARASITIC INFECTIONS | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-04-09 | — | — | EP | disclosed |
| EP-3634959-B1 | QUINOLINE DERIVATIVES FOR TREATING INFECTIONS WITH HELMINTHS | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-02-26 | — | — | EP | disclosed |
| EP-3585791-B1 | NEW BICYCLIC PYRAZOLE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2024-10-16 | — | — | EP | disclosed |
| EP-4426699-A1 | ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2024-09-11 | — | — | EP | disclosed |
| US-20240254133-A1 | ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-08-01 | — | — | US | disclosed |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8350083-B2 | Antagonists of the TRPV1 receptor and uses thereof | ABBVIE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2450346-A1 | Antagonists of the TRPV1 receptor and uses thereof | Abbott Laboratories (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120101287-A1 | Amino-1,3,5-triazines N-substituted with chiral bicyclic radicals, process for their preparation, compositions thereof, and their use as herbicides and plant growth regulators | BAYER CROPSCIENCE AG (DE) | 2012-04-26 | — | — | US | disclosed |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-8030504-B2 | Pain, especially, inflammatory hyperalgesia, ostheoarthritic pain, chronic lower pain, allodynia, migraine. Methods of controlling pain and treating bladder overactivity and urinary incontinence | ABBOTT LABORATORIES (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2305655-A2 | Amino-1,3,5-triazines N-substituted with chiral bicyclic radicals, process for their preparation, compositions thereof, and their use as herbicides and plant growth regulators. | Bayer CropScience AG (DE) | 2011-04-06 | — | — | EP | disclosed |
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| EP-1592674-A1 | AMINO 1, 3, 5-TRIAZINES N-SUBSTITUTED WITH CHIRAL BICYCLIC RADICALS, PROCESS FOR THEIR PREPARATION, COMPOSITIONS THEREOF AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | Bayer CropScience GmbH (DE) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069814-A1 | AMINO 1, 3, 5-TRIAZINES N-SUBSTITUTED WITH CHIRAL BICYCLIC RADICALS, PROCESS FOR THEIR PREPARATION, COMPOSITIONS THEREOF AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE GMBH (DE) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | DPP4 2733/4885HTR2A 197/4885ITGB2 3021/4885 |
| US-20120101287-A1 | Amino-1,3,5-triazines N-substituted with chiral bicyclic radicals, process for their preparation, compositions thereof, and their use as herbicides and plant growth regulators | IL4I1, DAO, CYP4Z1 | DPP4 844/4885HTR2A 2238/4885ITGB2 4730/4885 |
| US-12391682-B2 | Isoquinoline derivatives and their use for the treatment of parasitic infections | RECQL, QTRT2, HRH1 | DPP4 3013/4885HTR2A 1899/4885ITGB2 2768/4885 |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | DPP4 497/4885HTR2A 1711/4885ITGB2 3532/4885 |
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | RECQL, QTRT2, NQO2 | DPP4 2371/4885HTR2A 1364/4885ITGB2 4350/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | DPP4 2466/4885HTR2A 200/4885ITGB2 2807/4885 |
| US-20240254133-A1 | ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS | IL5, EPX, MPO | DPP4 176/4885HTR2A 4447/4885ITGB2 4197/4885 |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | DPP4 2733/4885HTR2A 197/4885ITGB2 3021/4885 |
| US-12559481-B2 | Quinoline derivatives | HRH1, HRH2, HRH4 | DPP4 1292/4885HTR2A 1790/4885ITGB2 3280/4885 |
| US-12435068-B2 | Anthelmintic compounds | H1-10, HRH2, HRH1 | DPP4 2695/4885HTR2A 2139/4885ITGB2 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.